Common genetic variants associated with urinary phthalate levels in children: a genome-wide study

3

4 Mariona Bustamante ^{a,b,c,*±}, Laura Balagué ^{a *}, Zsanett Buko^d, Amrit Kaur Sakhi^e, Maribel Casas^{a,b,c},

5 Lea Maitre^{a,b,c}, Sandra Andrusaityte^f, Regina Grazuleviciene^f, Kristine B Gützkow^e, Anne Lise

6 Brantsæter^e, Barbara Heude^g, Claire Philippat^h, Leda Chatziⁱ, Marina Vafeiadi ^j, Tiffany C Yang^k,

7 John Wright^k, Amy Hough^k, Carlos Ruiz-Arenas^m, Ramil Nurtdinovⁿ, Geòrgia Escaramís^{l,c}, Juan

- 8 Ramon Gonzalez^{a,b,c}, Cathrine Thomsen^e, Martine Vrijheid^{a,b,c}
- 9
- ^aEnvironment and Health over the Lifecourse, ISGlobal, Barcelona, Spain
- ^bUniversitat Pompeu Fabra (UPF), Barcelona, Spain
- 12 ^cCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- ¹³ ^dDepartment of Oncological Science, Huntsman Cancer Institute, Salt Lake City, United States of
- 14 America
- 15 ^eDivision of Climate and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway
- 16 ^fDepartment of Environmental Science, Vytautas Magnus University, Kaunas, Lithuania
- 17 ^gUniversité Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAE, Center for Research in
- 18 Epidemiology and StatisticS (CRESS), F-75004 Paris, France
- 19 ^hUniversity Grenoble Alpes, Inserm U-1209, CNRS-UMR-5309, Environmental Epidemiology
- 20 Applied to Reproduction and Respiratory Health Team, Institute for Advanced Biosciences, 38000,
- 21 Grenoble, France
- ⁱDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California,
- 23 Los Angeles, California, USA
- ^jDepartment of Social Medicine, Faculty of Medicine, University of Crete, Heraklion, Greece
- ^kBradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust,
 Bradford, UK
- 27 ¹Departament de Biomedicina, Institut de Neurociències, Universitat de Barcelona (UB), Barcelona,
- 28 Spain
- 29 ^mComputational Biology Program, CIMA University of Navarra, Pamplona, 31008, Spain
- 30 ⁿCentre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology,
- 31 Barcelona 08003, Catalonia, Spain
- 32
- **33** ^{*}Equal contribution
- 34
- 35 [±]Corresponding author:
- 36 Mariona Bustamante
- 37 <u>mariona.bustamante@isglobal.org</u>
- 38 ISGlobal
- 39 Dr. Aiguader 88
- 40 08003

- 41 Barcelona
- 42 Spain
- 43
- 44

45 Highlights

- 46
- The genetic variation involved in phthalate detoxification in humans is partially known.
- We identified four loci at genome-wide significance, and 113 at suggestive significance, some of
 them being novel.
- Two copy number variants were also identified.
- Functional annotation highlighted genes in phase I and II detoxification and renal excretion.
- 52
- 53

54 Abstract

55

56 Introduction: Phthalates, or dieters of phthalic acid, are a ubiquitous type of plasticizer used in a 57 variety of common consumer and industrial products. They act as endocrine disruptors and are 58 associated with increased risk for several diseases. Once in the body, phthalates are metabolized 59 through partially known mechanisms, involving phase I and phase II enzymes.

60

61 **Objective:** In this study we aimed to identify common single nucleotide polymorphisms (SNPs) and 62 copy number variants (CNVs) associated with the metabolism of phthalate compounds in children 63 through genome-wide association studies (GWAS).

64

65 **Methods:** The study used data from 1,044 children with European ancestry from the Human Early 66 Life Exposome (HELIX) cohort. Ten phthalate metabolites were assessed in a two-void urine pool 67 collected at the mean age of 8 years. Six ratios between secondary and primary phthalate metabolites 68 were calculated. Genome-wide genotyping was done with the Infinium Global Screening Array 69 (GSA) and imputation with the Haplotype Reference Consortium (HRC) panel. PennCNV was used 70 to estimate copy number variants (CNVs) and CNVRanger to identify consensus regions. GWAS of 71 SNPs and CNVs were conducted using PLINK and SNPassoc, respectively. Subsequently, functional 72 annotation of suggestive SNPs (p-value <1E-05) was done with the FUMA web-tool.

73


Results: We identified four genome-wide significant (p-value <5E-08) loci at chromosome (chr) 3 (*FECHP1* for oxo-MiNP_oh-MiNP ratio), chr6 (*SLC17A1* for MECPP_MEHPP ratio), chr9 (*RAPGEF1* for MBzP), and chr10 (*CYP2C9* for MECPP_MEHPP ratio). Moreover, 113 additional loci were found at suggestive significance (p-value <1E-05). Two CNVs located at chr11 (*MRGPRX1* for oh-MiNP and *SLC35F2* for MEP) were also identified. Functional annotation pointed to genes involved in phase I and phase II detoxification, molecular transfer across membranes, and renal excretion.

82 Conclusion: Through genome-wide screenings we identified known and novel loci implicated in

phthalate metabolism in children. Genes annotated to these loci participate in detoxification and renal
 excretion.

- 85
- 86

87 Graphical abstract:



88

89 Keywords: phthalate, genome-wide association study (GWAS), genetic variant, single nucleotide

- 90 polymorphism (SNP), copy number variant (CNV), metabolism, toxicity, phase I and II enzymes,
- 91 renal excretion
- 92

93 Abbreviations

- 94
- 95 **ABC:** ATP-binding cassette
- 96 **BBP:** butylbenzyl phthalate
- 97 chr: chromosome
- 98 CNV: copy number variant
- 99 **CYP:** Cytochrome P450 monooxygenase
- 100 **DBzP:** dibenzyl phthalate
- 101 **DEP:** diethyl phthalate
- **DEHP:** bis(2-ethylhexyl) phthalate
- 103 **DiBP:** diisobutyl phthalate
- 104 DINCH: 2-cyclohexane dicarboxylic acid, diisononyl ester
- 105 **DnBP:** di-n-butyl-phthalate
- **EDCs:** endocrine disrupting chemicals
- 107 **GSA:** Infinium Global Screening Array
- 108 **GWAS:** genome-wide association study
- 109 HELIX: Human Early Life Exposome project
- 110 HMW: high-molecular-weight

- 111 **HRC:** haplotype reference consortium
- 112 LD: linkage disequilibrium
- 113 LMW: low-molecular-weight
- 114 **MBzP:** mono benzyl phthalate
- **MECPP:** mono-2-ethyl-5-carboxypentyl phthalate
- **MECPP_MEHP:** ratio between MECPP and MEHP
- **MECPP_MEHHP:** ratio between MECPP and MEHHP
- **MEHHP:** mono-2-ethyl-5-hydroxyhexyl phthalate
- **MEHHP_MEHP:** ratio between MEHHP and MEHP
- 120 MEHP: mono-2-ethylhexyl phthalate
- 121 MEOHP: mono-2-ethyl-5-oxohexyl phthalate
- 122 **MEOHP_MEHP:** ratio between MEOHP and MEHP
- 123 **MEOPP_MEHHP:** ratio between MEOPP and MEHHP
- 124 MEP: monoethyl phthalate
- 125 MiBP: mono-iso-butyl phthalate
- 126 MnBP: mono-n-butyl phthalate
- 127 oh-MiNP: mono-4-methyl-7-hydroxyoctyl phthalate
- 128 oxo-MiNP: mono-4-methyl-7-oxooctyl phthalate
- 129 oxo-MiNP_oh-MiNP: ratio between oxo-MiNP and oh-MiNP
- 130 **PVC:** polyvinyl chloride
- 131 **QQ**: quantile-quantile
- 132 SCL: Solute carrier
- 133 SNP: single nucleotide polymorphism
- 134 SULT: Sulfotransferase
- 135 UGT: UDP-glucuronosyltransferase
- 136
- 137

138 1. Introduction

139

140 Phthalates, or dieters of phthalic acid, are a ubiquitous type of plasticizer used in a variety of 141 common consumer and industrial products, whose exposure is widespread and ever-changing due to 142 our constantly evolving environment and habits (Praveena et al., 2018; Wang et al., 2019). Phthalates 143 are known to be endocrine disrupting chemicals (EDCs), and epidemiological research has suggested 144 that exposure to phthalates is associated with increased risk for several diseases including infertility, 145 allergy, obesity, diabetes, and behavioral problems (Praveena et al., 2018; Wang et al., 2019). Since 146 children are especially vulnerable to contaminants as they are still developing, there is a great 147 concern over the potential for phthalate exposure to disturb normal growth and development (Braun, 148 2017; Casale and Rice, 2023; Lee et al., 2022, 2023).

149

150 Phthalates can be separated into low-molecular-weight (LMW, 3-6 carbon atoms) and high-151 molecular-weight (HMW, 7-13 carbon atoms) compounds (Praveena et al., 2018; Wang et al., 2019). 152 LMW phthalates are used as solvents and are usually found in medications and personal care items 153 such as deodorants, lotions, and shampoos. HMW phthalates are used in the manufacturing of 154 flexible plastics for purpose of vinyl flooring, adhesives, medical devices, and food packaging. The 155 main intake of LMW phthalates is through skin and inhalation, while HMW phthalates are 156 incorporated into the body through ingestion (Kim and Park, 2014). In the European Union, some 157 phthalates are now banned from use in cosmetics and regulated in material intended to come into 158 contact with food.

159

160 After exposure, phthalates are rapidly metabolized and excreted mainly in urine as a result of phase I 161 and phase II enzymes (Domínguez-Romero and Scheringer, 2019; Praveena et al., 2018). First, 162 diester phthalates are hydrolyzed to monoester (primary metabolites) by phase I esterase and lipase 163 enzymes (Bhattacharyya et al., 2022). Subsequently, LMW phthalates are primarily excreted in urine 164 and feces as monoesters, without further metabolism. In contrast, HMW phthalates need further 165 metabolism through hydroxylation and oxidation by phase I enzymes thus producing a number of 166 oxidative metabolites (secondary metabolites). These oxidated metabolites can be directly excreted in 167 the urine, or alternatively, can be additionally metabolized through phase II enzymes. Phase II 168 detoxification consists of conjugation reactions where a compound is added to the parental 169 compound to generate hydrophilic conjugates which can then be easily excreted in the urine. 170 Phthalates and their metabolites can be measured in diverse biological specimens, such as blood, 171 urine, breast milk, and feces. However, urinary phthalate metabolites are the most frequently used 172 biomarkers to track exposure to phthalates (Sakhi et al., 2017; Wang et al., 2019).

173

Phase I and phase II enzymes are highly polymorphic in humans, with slow and fast metabolic phenotypes determined by single nucleotide polymorphisms (SNPs) and copy number variants (CNVs) (Pinto and Eileen Dolan, 2011). This differential detoxification capacity might modify phthalate effects in the body and is rarely considered in epidemiological studies. In vitro studies demonstrated the importance for phthalate metabolism of genetic polymorphisms in *Cytochrome P450 (CYP) monooxygenases*, a family of phase I detoxification enzymes (Choi et al., 2012).

Moreover, in humans, urinary phthalate metabolite levels were reported to be associated with genetic

variants in *CYP monooxygenases* (*CYP2C9* and *CYP2C19*) and in *UDP-glucuronosyltransferases*(*UGT1A7*) in young adults (Stajnko et al., 2022), and with variants in *GSTP1* and *SOD2* in children
(Wang and Karmaus, 2017). However, these studies were based on a priori knowledge of candidate
genes and SNPs, likely missing additional loci important for phthalate metabolism. Genome-wide
association studies (GWAS), which allow the interrogation of millions of common genetic variants,
both SNPs and CNVs, can help to overcome this limitation and reveal new phthalate detoxification
pathways (Visscher et al., 2017).

187 188

180

Here, we aimed to identify genetic variants related to phthalate metabolism in children. For this, we
analyzed the association of genome-wide SNPs and CNVs with urinary levels of ten phthalate
metabolites and six phthalate ratios in 1,044 European ancestry children from the Human Early Life
Exposome (HELIX) project and performed functional annotation of the identified variants.

193 194

2. Materials and methods

195 196 197

198

2.1. Study population

199 HELIX project is an ongoing population-based birth control study in six birth cohorts from different 200 European countries: (1) EDEN - Étude des Déterminants pré et postnatals du développement et de la 201 santé de l'enfant, France; (2) Rhea - the Rhea Mother-Child Study in Crete, Greece; (3) KANC -202 Kaunus Cohort, Lithuania; (4) MoBa – the Norwegian Mother, Father and Child Cohort Study, 203 Norway; (5) INMA - - INfancia y Medio Ambiente, Spain; (6) BiB - Born in Bradford, United 204 Kingdom (UK) (Maitre et al., 2018). The HELIX project aims to implement novel exposure 205 assessment and biomarker methods to measure the early-life exposure to multiple environmental 206 factors and associate these with omics biomarkers and child health outcomes, thus characterizing the 207 "early-life exposome". The entire study population is 31,472 mother-child pairs. The subcohort study 208 includes 1,304 children with exposure, phenotypes, and molecular data measured at age of 6-12 209 years. The current study selected 1,044 children of European ancestry with genome-wide genetic and 210 phthalate metabolite levels available from the HELIX subcohort (Appendix A - Supplementary 211 Figure 1). Child's ancestry was predicted from genome-wide genetic data. The following variables 212 were used to describe the population: child's sex (male/female), child's age (in years), child's obesity 213 in 3 categories (normal, overweight, obese) based on the World Health Organization (WHO) body 214 mass index (BMI) classification, and self-reported maternal education (primary, secondary and 215 university or higher).

216

217 218

2.2. Ethics approval and consent to participate

All studies were approved by the national research ethics committees and informed consent toparticipate was obtained for all participants.

222 2.3. Phthalate biomarkers measurement

223

Metabolites for 6 different phthalates were measured in a pool of two urine samples collected in the morning and at bedtime at the mean age of 8 years (Figure 1).

226

227 An aliquot of the urine pool was analyzed for the determination of four LMW primary phthalate 228 metabolites [monoethyl phthalate (MEP), mono-n-butyl phthalate (MnBP), mono-isobutyl phthalate 229 (MiBP), mono benzyl phthalate (MBzP)], one HMW primary phthalate metabolite [mono-2-230 ethylhexyl phthalate (MEHP)], and five HMW secondary metabolites [mono-2-ethyl-5-231 hydroxyphenyl phthalate (MEHHP), mono-2-ethyl-5-oxohexyl phthalate (MEOHP), mono-2-ethyl-5-232 oxyhexyl phthalate (MECPP), mono-4-methyl-7-hydroxyoctyl phthalate (oh-MiNP), and mono-4-methyl-7-oxooctyl phthalate (oxo-MiNP)], using high performance liquid chromatography 233 234 coupled to mass spectrometry (Haug et al., 2018). Both external control samples, in-house control 235 samples and blank samples were analyzed in each batch of about fifty samples. The limits of 236 detection (LOD) of the method ranged from 0.067 to 0.67 ng/mL. All the samples had values >LOD. 237 MEHP, MEHHP and MEOHP had 34, 3 and 1 missing values, due to underperformance of sample 238 quantification.

239

240 To account for urine dilution, a second aliquot of urine was analyzed for creatinine concentration, 241 and phthalate metabolite concentrations were divided by urinary creatinine levels (Haug et al., 2018). 242 All creatinine-adjusted concentrations were log2 transformed to obtain normal distributions, as the 243 original distributions were right-skewed. Finally, as a proxy of enzymatic activity, we calculated six 244 ratios between product and substrate, in our case, between secondary and primary phthalate 245 metabolites or between two secondary phthalate metabolites, as follows: MECPP_MEHP, 246 MEHHP_MEHP, MEOHP_MEHP, MECPP_MEHHP, MEOHP_MEHHP and oxo-MiNP_oh-MiNP. 247 The ratios were calculated using untransformed phthalate values unadjusted for creatinine, and then 248 they were log2 transformed. Urine dilution was not taken into account as the ratios were computed 249 using two compounds within the same urine sample.

- 250
- 251 2.4. Genetic data
- 252

DNA was obtained from buffy coats collected in EDTA tubes at the mean age of 8 years. DNA was
extracted by cohort using a Chemagen kit in batched of 12 samples. Two techniques were used to
determine the DNA concentration 1) NanoDrop 1000 UV-Vis Spectrophotometer (ThermoScientific)
and 2) Quant-iTTM PicoGreen® dsDNA Assay Kit (Life Technologies).

257

Infinium Global Screening Array (GSA) MD version 1 (Illumina) was used for genome-wide genotyping at the Human Genomics Facility (HuGe-F), Erasmus MC (www.glimdna.org). Genotype calling and annotation were done using the GenTrain2.8 algorithm based on a custom cluster file implemented in the GenomeStudio software and the GSAMD-24v1-0_20011747-A4 manifest. SNP coordinates were reported on human reference GRCh37 and on the source strand.

264 PLINK program was used for the quality control of the genetic data (Purcell et al., 2007). Briefly, 265 samples were filtered out if they had a call rate <97%, had sex inconsistencies, the heterozygosity 266 was >3 standard deviations, if they were related (sharing >18.5% of alleles) or duplicated. For 267 ancestry prediction from GWAS data, we used the Peddy program (Pedersen and Quinlan, 2017). 268 Then genetic ancestry was contrasted with self-reported ethnicity and discordant samples were 269 excluded. Genetic variants were filtered out if they had a call rate <95%, if they were in the non-270 canonical pseudo-autosomal region (PAR), if they had a minor allele frequency (MAF) <1%, and if 271 they were not in Hardy-Weinberg equilibrium (HWE) at a p-value <1E -06. PLINK was also used to 272 compute the first 20 principal components from the GWAS data of European ancestry children using 273 the linkage disequilibrium (LD) clumping option. Ten PCs explained up to 19.2% of the genetic 274 variance and the five first ones correlated with cohort.

275

Genome-wide imputation was performed with the Imputation Michigan server using the Haplotype Reference Consortium (HRC) panel, Version r1.1 2016. Before the imputation PLINK data was converted into VCF format and the variants were aligned with the reference genome. Eagle v2.4 was used for the phasing of the haplotypes and minimac4 for the imputation. In the end, we retrieved 40,405,505 variants after imputation. Then we filtered out the genetic variants according to the following parameters: imputation accuracy (R2) <0.9, MAF<5%, and HWE p-value <1E-06. After this the post-imputation dataset had 4,614,947 variants.

283

284 2.5. GWAS of SNPs

285

286 GWAS of SNPs were conducted with the PLINK program by applying a linear regression model for 287 each phthalate metabolite and each SNP from chromosome 1 to 22, adjusting for sex, age and ten 288 GWAS principal components as a proxy of ancestry (PCs) (Purcell et al., 2007). We run a total of 16 289 GWAS (five primary metabolites, five secondary metabolites, and six ratios). Genome-wide 290 statistical significance was established at a p-value <5E-08, and suggestive statistical significance at 291 a p-value <1E-5. The lambda genomic inflation factor was estimated as the median of the resulting 292 chi-squared test statistics divided by the expected median of the chi-squared distribution. Quantile-293 quantile (QQ) plots were conducted with the ggplot2 package and Manhattan plots were conducted 294 with the qqman package in R (D. Turner, 2018; Wickham, 2016). The lead SNP is defined as the 295 SNP with the lowest p-value in a locus, and a locus is defined as a region of 1Mb.

296

In order to filter out associations between the SNPs and creatinine levels, we run sensitivity models
adjusting for log2 transformed creatinine levels, instead of controlling (dividing) the phthalate
concentrations by creatinine. Finally, we also run a GWAS for log2 transformed creatinine levels (g
per L of urine).

- 301
- 302 *2.6. GWAS of CNVs*
- 303

Copy number variant (CNV) calls were obtained with PennCNV using BAF/LRR signal files from
Illumina BeadStudio (Wang et al., 2007). A total of 22 samples from the initial 1,044 had to be

removed due to poor quality in BAF or LRR values. After that, CNV calls overlapping with the 306 307 centromeres were filtered out. After the quality control, consensus CNV regions were obtained with 308 the CNVRanger R package following the reciprocal overlap procedure, that merges calls with 309 sufficient mutual overlap, in our case 50% (Conrad et al., 2010; Da Silva et al., 2020). From the 310 resulting consensus regions, only common CNVs with an alternative minor allele frequency (either 311 gain or loss) >3% were kept for the analysis. Consensus CNV regions were classified into: (i) only 312 loss, when we only detected deletions (CN=0 and CN=1); (ii) only gain, when we only detected 313 duplications (CN=3; note that more than 3 copies were never detected); and (iii) loss and gain, when 314 we detected both deletions and duplications (CN=0, CN=1 and CN=3).

315

316 Association analyses between each of the resulting regions and each of the 16 metabolites and ratios 317 were performed with SNPassoc R package (González et al., 2007). Distinct association models were 318 applied to each region based on the prior CNV classification. For only-loss regions we tested loss-319 codominant (0 vs 1 vs 2), loss-dominant (0+1 vs 2), loss-recessive (0 vs 1+2), loss-overdominant 320 (0+2 vs 1) and loss-log-additive models; and for only-gain regions we tested gain-codominant (2 vs 321 3) model. Finally, for loss-and-gain regions we tested all loss-specific and gain-specific models 322 above, as well as an additive lineal model taking into account loss and gain. All analyses were 323 adjusted for the same covariates as the GWAS of SNPs (sex, age and ten GWAS principal 324 components (PCs)). Multiple-testing correction was conducted by dividing the nominal p-value of 325 0.05 by the number of detected consensus CNVs (0.05/36 = 0.0014). As was done with SNPs, 326 sensitivity models adjusting for log2 transformed creatinine levels were investigated in order to filter 327 out associations between the CNVs and creatinine levels. Finally, we also run a model for log2 328 transformed creatinine levels (g per L of urine).

329

Annotation of genes in each CNV region was done with the biomaRt R package (Durinck et al.,2009).

- 332
- 333
- 334 335

2.7. Functional annotation of genetic variants, gene-wide association analysis and enrichment

336 For the annotation, prioritization, and biological interpretation of the genetic variants identified in the 337 GWAS, we used the Functional Mapping and Annotation of Genome-Wide Association Studies 338 (FUMA) tool (Watanabe et al., 2017). The SNP2GENE module computes LD structure, annotates 339 SNPs using information from different databases, and prioritizes candidate genes. FUMA was run 340 using default parameters except that the p-value threshold was set to 1E-05 instead of 1E-08. For the 341 SNP annotation we used: ANNOVAR, CADD, RegulomeDB, expression quantitative trait locus 342 (eQTL) mapping based on Genotype-Tissue Expression (GTEx) v8 and other databases, comparison 343 with SNPs reported in the GWAS catalog and gene mapping through chromatin interaction maps. 344 Then, with the GENE2FUNC module from FUMA prioritized genes from SNP2GENE module were 345 used to identify shared molecular functions using different databases: Gene Ontology (GO) terms, 346 Kyoto Encyclopedia of Genes and Genomes (KEGG), and Reactome, among others. GENE2FUNC 347 was also used to assess enrichment for 54 tissues included in the GTEXv8 dataset.

348

For gene mapping through chromatin interaction we also used the EPIraction tool (Nurtdinov and Guigó, n.d.). Briefly, the tool contains a catalogue of tissue specific gene-enhancer interactions identified by applying linear models between gene expression and activities of nearby enhancers across 1,529 samples from 77 different tissues. In this study, we annotated SNPs to enhancers and then linked enhancers to genes in two candidate tissues for phthalate detoxification: liver and kidney.

- 355
- 356
- **357 3. Results**
- 358 359

360

3.1. Description of the population

361 The description of the 1,044 HELIX participants is shown in Table 1. All participants were of 362 European ancestry and from six different countries: Greece, Norway, Spain, Lithuania, France, and 363 the UK. Forty-six percent of the participants were female, and the mean age of phthalate 364 measurements was 8 years (standard deviation (SD): 1.6). Around half of the children were born 365 from highly educated mothers. Urinary phthalate levels (micrograms (µg) per gram (g) of creatinine) 366 were in the range or higher than levels reported in children and adolescents from 12 European 367 countries for the period 2014–2021 (Vogel et al., 2023). After log2 transformation, levels tended to 368 be normally distributed and the correlation among them ranged from 0.18 to 0.98 (Appendix A – 369 Supplementary Figure 2). Highest correlations (r>0.79) were observed among MECPP, MEHHP, 370 MEOHP, MEHP, which are all primary or secondary metabolites of the same parental compound, 371 DEHP. The correlation of oh-MiNP and oxo-MiNP was also high (R=0.73).

372 373

3.2. GWAS of SNPs

To identify SNPs associated with the detoxification metabolism of phthalates in children, we run
linear regressions for each of the ten phthalate metabolites and the six metabolic ratios adjusting for
sex, age, and 10 GWAS principal components.

378

379 Genomic inflation factors (lambdas) ranged from 0.989 to 1.021 (Appendix A – Supplementary 380 Figure 3). Four loci reached genome-wide significance (p-value <5E-08) as shown in the Miami plot 381 (Figure 2). They involved two SNPs at chr3 associated with the oxo-MiNP_oh-MiNP ratio (lead SNP 382 rs80064213 C, effect = 0.331, p-value = 4.15E-08, near *FECHP1* gene), 116 SNPs at chr6 383 associated with the MECPP MEHPP ratio (rs1359232 A, effect = -0.134, p-value = 4.58E-17, 384 SLC17A1), one SNP at chr9 associated with MBzP (rs138702233 T, effect = 0.394, p-value = 4.29E-385 08, RAPGEF1), and 658, 186 and 369 SNPs at chr10 associated with the MECPP MEHPP, 386 MEOHP_MEHHP and MECPP_MEHP ratios, respectively (rs74494115_T, effect = -0.309, p-value 387 = 1.45E-63, CYP2C9). The locus zoom plots of these four loci are shown in Figure 3.

389 Moreover, 2,140 SNPs representing 158 loci (113 unique) were identified at suggestive significance 390 (p-value <1E-05) for at least one phthalate metabolite or ratio (Table 2, Appendix B - Supplementary 391 Table B1). The number of loci with suggestive statistical significance per phthalate metabolite or 392 ratio was between five and 15. Thirty of the 117 suggestive or genome-wide significant unique loci 393 were shared between more than one phthalate compound or ratio (Appendix A – Supplementary 394 Figure 4). The genome-wide significant loci at chr3 (FECHP1), chr6 (SLC17A1) and chr10 395 (CYP2C9), also had suggestive associations with other phthalate compounds or ratios (Table 3, 396 Appendix B – Supplementary Table B1).

397

398 Sensitivity analysis adjusting for creatinine instead that using it to divide phthalate metabolite levels 399 gave similar results with minor differences (Appendix B - Supplementary Table B2). Three of the 400 four genome-wide significant loci had still a p-value <1E-08, and the other hit (chr9 loci associated 401 with MBzP) was marginally significant (p-value = 9.95E-07). A plot comparing p-values and effect 402 sizes between the two models for all the suggestive SNPs can be seen at Appendix A – 403 Supplementary Figure 5A and 5B. Moreover, the GWAS of creatinine levels did not retrieve any 404 genome-wide significant SNP. Only two of the creatinine suggestive SNPs were also suggestively 405 associated with MEOHP and oh-MiNP (Appendinx B Supplementary Table B19).

- 406
- 407 *3.3. GWAS of CNVs*
- 408

409 Using the PennCNV tool, we identified a median of seven (interquartile range (IQR): 6-9) CNV 410 regions per child with a median length of 43 (IQR: 29-64) kb. Only two children did not present any 411 CNV event. After applying a reciprocal overlap of 50%, 2,916 distinct CNV regions were detected, 412 including 1,785 that were unique, meaning that they were detected in only one child. Thirty-six of the 413 2,916 CNVs were identified in > 3% of the children and thus labeled as consensus CNV regions and 414 tested in relation to phthalate levels and ratios (Appendix C – Supplementary Table C0).

415

In 12 of the 36 consensus regions, we detected single or double deletions (loss CNVs, CN=0 and CN=1), in seven of them we detected single duplications (gain CNVs, CN=3) and in 17 of them we detected single and double deletions as well as single duplications (loss and gain CNVs, CN=0, CN=1 and CN=3). We did not detect double duplications (CN=4) in any CNV consensus region. Different models were tested in each type of region (see 2.6.) and the model with the highest significance was reported for each region. The results of the association of these common CNVs with phthalate levels and ratios can be found in Appendix C – Supplementary Tables C3-18.

423

Fifty-one CNVs presented nominal significance and two of them passed multiple-testing correction (Figure 2, Appendix C - Supplementary Table C1). First, a single-copy gain in CNV region 11A was associated with higher oh-MiNP levels (chr11:18.95Mb-18.96Mb_gain, effect = 1.231, p-value = 1.77E-06, *MRGPRX1* gene), and second, a single-copy gain in CNV region 11B was associated with higher MEP levels (chr11:107.65Mb-107.67Mb_gain, effect = 0.792, p-value = 1.36E-03, *SLC35F2*).

429 The locus zoom plots of these two CNVs are shown in Figure 4.

431 In the sensitivity analysis adjusting for creatinine, the 88% of the nominally significant associations 432 were reproduced (45 of 51). The associations between CNV 11A and oh-MiNP and between CNV 433 11B and MEP were very similar (Appendix C - Supplementary Table C2), however the later did not 434 reach the multiple-testing threshold (chr11:18.95Mb-18.96Mb_gain, effect = 1.120, p-value = 2.51E-435 06; chr11:107.65Mb-107.67Mb gain, effect = 0.695, p-value = 1.48E-03). A plot comparing p-values 436 and effect sizes between the two models for all the suggestive CNVs can be seen at Appendix A – 437 Supplementary Figure 5C and 5D. Results for creatinine GWAS did not show any significant 438 association, with only four CNV regions, not including 11A and 11B, showing a p-value <0.05439 (Appendix C - Supplementary Table C19).

- 440
- 441 442

3.4. Functional annotation of genetic variants and identification of candidate genes and pathways

443 Next, SNPs with suggestive significance were explored with the FUMA tool providing information 444 on SNP annotation (Appendix D), identification of eOTLs (Appendix E), and comparison with SNPs 445 in the GWAS catalog (Appendix F). Appendix G shows the list of candidate genes in each locus 446 based on FUMA results and gene-enhancer interactions from the EPIraction tool. A selection of 12 interesting loci in terms of statistical significance, annotated genes and/or overlap with GWAS traits 447 is listed in Table 3. These loci are annotated to phase I and phase II detoxification genes [CYP 448 449 monooxygenases (CYP2C cluster), Sulfotransferases (SULT1B1, SULT1E1, and SULT1C3), UDP 450 glucuronosyltransferases (UGT2A1, UGT2A2 and UGT2B11), and glutathione related genes (GSR, 451 *GPX5* and *GPX6*]; and genes related to molecule transport across membranes [Solute carriers] 452 (SLC17A cluster, SLC8A2, and SLC35G1) and others such as ABCC3, ATP9B and STAC].

453

454 After the FUMA annotation, we took suggestive prioritized genes to run gene-set enrichment
455 analyses (Appendix H). Among others, we identified gene-sets related to xenobiotic detoxification,
456 drug detoxification, CYP, oxidoreductase reactions, liver, phase I and phase II enzymes. These gene457 sets were found basically for MEP, MECPP and its ratios, and MEOHP ratios.

458

Finally, we searched for enriched GTEXv8 tissues (Appendix I). At adjusted and/or nominal
statistical significance, we found enrichment for candidate tissues involved in phthalate metabolism:
liver (MEOHP_MEHP and MEOPH_MEHHP), kidney cortex (MBzP, MECPP_MEHP and
MEOHP_MEHHP), and bladder (MECPP_MEHP). Other significant enrichments were found for
skin and vagina (oxo-MiNP_oh-MiNP), artery aorta (MiBP), and nerve tibial (MEHP).

464 465

4. Discussion

466

In this study we conducted genome-wide screenings of SNPs and CNVs in order to identify genetic
variation associated with phthalate metabolism in children. We identified four genome-wide
significant loci at chr3 (*FECHP1* – oxo-MiNP_oh-MiNP), chr6 (*SLC17A1* – MECPP_MEHPP), chr9
(*RAPGEF1* – MBzP) and chr10 (*CYP2C9* – MECPP_MEHPP) and two significant CNVs located at
chr11 (*MRGPRX1* – oh-MiNP and *SLC35F2* – MEP). Functional annotation of suggestive SNPs
highlighted pathways related to xenobiotic and drug detoxification. Also some of the genes annotated

to the SNPs associated with phthalates showed significant enrichment for key tissues as liver and kidney, which is indicative of high gene expression levels in these tissues. Furthermore, previous GWAS have reported significant associations of SNPs located in these loci with drug biotransformation and urinary metabolite levels of several compounds. Below we describe in detail the most relevant loci and genes identified, which are related to phase I and II metabolism, transport of molecules across membranes and kidney function.

479

480 *4.1. Phase I metabolism*

481

482 We identified three loci annotated to CYP genes, one of them achieving the smallest p-value of the 483 study. This top locus at chr10 was associated with four DEHP metabolite ratios (MECPP_MEHPP; 484 MECPP_MEHP; MEOHP_MEHHP; MEOHP_MEHP) and contains CYP2C8, CYP2C9, CYP2C18, 485 and CYP2C19 genes. According to the EPIraction tool, the locus can act as an enhancer of these 486 genes in liver and/or kidney. CYP genes code for phase I monooxygenases that are key in multitude 487 of metabolic processes of endogenous and exogenous compounds, and, indeed, SNPs in this locus 488 have previously been reported to be associated with serum or plasma levels of several metabolites or 489 proteins (Feofanova et al., 2020; Pazoki et al., 2021; Schlosser et al., 2020) and drug response (ie. 490 warfarin) (Takeuchi et al., 2009). Moreover, CYP2C enzymes are known to participate in phthalate 491 metabolism, and CYP2C9 variants have been associated with the biotransformation of MEHP into 492 secondary metabolites in young adults (Stajnko et al., 2022). Our study confirms that similar 493 detoxification mechanisms take place in children. The two additional CYP loci, one at chr7 harboring 494 CYP2W1 and the other at chr19 including CYP2A6, CYP2B6, CYP2A13 and CYP2S1, showed 495 suggestive associations with urinary MEP levels (metabolite of diethyl phthalate (DEP)). Therefore, 496 according to our results, DEP (LMW phthalate present in many personal care products, particularly 497 those containing fragrances) and DEHP (HMW phthalate mainly used for food packaging) seem to 498 be metabolized through different CYP genes.

- 499
- 500
- 501

4.2. Phase II metabolism

502

503 We also identified several loci annotated to phase II metabolism genes, including 504 $UDP \square$ glucuronosyltransferases (UGTs), Sulfotransferases (SULTs) and Glutathione $S \square$ transferases 505 (GSTs). First, we found a locus at chr4, annotated to UGT2B11, UGT2A1 and UGT2A2, to be 506 suggestively associated with levels of MnBP, a metabolite of di-n-butyl-phthalate (DnBP), which is 507 found in paints, adhesives, personal care products and deodorants. SNPs in another family member, 508 UGT1A7, were previously related to urinary levels of 2-cyclohexane dicarboxylic acid, diisononyl 509 ester (DINCH) metabolite in men and of diisobutyl phthalate (DBP) and dibenzyl phthalate (DBzP) 510 metabolites in women (Stajnko et al., 2022). Notably, DiBP and DnBP are structural isomers. 511 Second, we found three loci annotated to *Sulfotransferases*: the same locus at chr4 associated with 512 MnBP also contained the SULT1B1 and SULT1E1 genes, and two additional suggestive loci at chr2 513 and chr19 harboring SNPs near SULT1C3 and SULT2B1 genes, respectively, that showed 514 associations with DEHP metabolites. Previous studies have described that multiple phthalates have

strong inhibition potential towards *SULT* enzymes, potentially causing reduced body detoxification and liver injury (Ceauranu et al., 2023; Huang et al., 2022). Finally, we identified two loci that contain genes that participate in the glutathione metabolism: a genome-wide significant locus at chr6 annotated to *GPX5*, *GPX6* and *SLC* genes associated with MEHP and oh-MiNP levels; and a suggestive locus at chr8 near *GSR*, a central enzyme of cellular antioxidant defence, associated with MEHP ratios. This is consistent with previous research reporting that in zebrafish, MEHP exposure alters the expression of *gsr* (Kwan et al., 2021).

522 523

524

4.3. Molecular transport across membranes and kidney function

- 525 Besides detoxification, we identified several loci annotated to transmembrane transporter genes 526 which could potentially play a role in the excretion of phthalates in the intestine or kidney. These 527 encompass several Solute carrier (SLC) genes that code for transporters of a wide array of substrates 528 across membranes (Liu, 2019). A locus at chr6 harboring SLC17A1, SLC17A2, SLC17A3 and 529 SLC17A4 was associated with MEHP ratios at genome-wide significance and showed suggestive 530 associations with oh-MiNP. Both gene-enhancer and eQTL information, suggested that these SNPs regulate SLC expression in liver and/or kidney. Moreover, it is known that SLC17A1 and SLC17A3 531 532 participate in urate regulation by facilitating the excretion of intracellular urate from the bloodstream 533 into renal tubule cells. Consistently, previous GWAS reported associations between this locus and 534 serum uric acid levels (Hollis-Moffatt et al., 2012), urinary metabolite levels (Schlosser et al., 2020), 535 estimated glomerular filtration rate (creatinine) (Stanzick et al., 2021), and chronic kidney disease 536 (Torres et al., 2021), among others. Besides, other associations involving the SLC family were 537 identified, including the association between a single-copy gain in a CNV that overlaps the final exon 538 and 3'UTR of the SLC35F2 gene, predicted to enable transmembrane transporter activity, and MEP 539 urinary levels.
- 540

541 ABCC3 encodes a member of the ATP-binding cassette (ABC) transporters that play a role in the 542 transport of biliary and intestinal excretion of organic anions. Moreover, it is reported to be involved 543 in multi-drug resistance (Deeley et al., 2006; Ramírez-Cosmes et al., 2021) and variants in the gene 544 are related to serum/plasma metabolite levels (Bruhn and Cascorbi, 2014). In our study, SNPs in the 545 ABCC3 intronic region (chr17) were found to be suggestively associated with the MEOHP MEHP 546 ratio. Notably, another study showed that flies exposed to dibutyl-phthalate (DBP) have increased expression of several genes, including an homologous of the ABCC3 gene (Williams et al., 2016). 547 548 Two more transporters were identified. On the one hand, SNPs in a liver and kidney enhancer for 549 ATP9B gene (chr18), which is predicted to enable ATPase-coupled intramembrane lipid transport, 550 were suggestively associated with DEHP metabolites and ratios. On the other hand, SNPs near STAC 551 (chr3) were associated with the oxo-MiNP_oh-MiNP ratio at genome wide significance and with the 552 MEOHP MEHHP ratio at suggestive significance. STAC is predicted to enable transmembrane 553 transporter binding activity and participate in positive regulation of voltage-gated calcium channels 554 and skeletal muscle contraction.

556 The last group of results is comprised by two genes potentially implicated in kidney function: 557 RAPGEF1 and MRGPRX1. First, SNPs located in a liver and kidney enhancer for RAPGEF1 at chr9 558 were genome-wide associated with MBzP, a metabolite of butylbenzyl phthalate (BBP) used as 559 plasticizer for polyvinyl chloride (PVC). RAPGEF1 encodes a guanine nucleotide exchange factor, 560 and mutations in genes of the same family have been found in patients with nephrotic syndrome type 561 7 and membranoproliferative glomerulonephritis (Maywald et al., 2022; Zhu et al., 2019). Second, a 562 loss-gain CNV of 10.8 kb overlapping the whole gene MRGPRX1 was associated with oh-MiNP, a 563 metabolite of DINP which is used primarily in the manufacture of PVC. MRGPRX1 encodes a Mas-564 related G-protein-coupled receptor reported to be responsible for itch sensation, pain transmission 565 and inflammatory reactions, including those to the antimalarial drug chloroquine (Gan et al., 2023). 566 Additionally, mutations in other G-protein-coupled receptors have been implicated in nephrogenic 567 diabetes insipidus, a disease characterized by polyuria and polydipsia (Wang et al., 2018). We found 568 that individuals with three copies of the gene had increased levels of urinary levels of oh-MiNP, 569 whereas individuals with zero or one copy had no difference versus the reference group with two 570 copies. Given the low numbers presenting the alternative allele, further investigation in a larger 571 sample would be required. 572

573 Our study found several associations between phthalates and SNPs known to regulate urinary 574 metabolite levels, glomerular filtration rate, and kidney function. These associations might indicate a 575 real participation of these SNPs in phthalate excretion. Nevertheless, as our phthalate measurements 576 were normalized by creatinine to account for urine dilution, some of our results could also just reflect 577 renal excretion capacity. Although both explanations are possible, there is some evidence supporting 578 the former. First, in vitro studies suggest that phthalates can be a substrate for the SLC transporters 579 (Klaassen and Aleksunes, 2010); second, the associations found with the phthalate ratios are 580 unaffected by the creatinine normalization; third the sensitivity model adjusting for creatinine instead 581 of normalizing by it provided similar results; and four the GWAS of creatinine did not found many 582 suggestive loci overlapping with loci found for phthalates.

- 583
- 584 585

4.4. Strengths of the study

586 The study has several strengths. First, we measured a large number of phthalate metabolites using a 587 robust analytical method in an equal volume daily pool of two urine samples (morning and night). 588 Second, instead of analyzing individual SNPs in candidate genes, we performed genome-wide 589 screenings of SNPs and CNVs and several downstream annotation methods that allowed us to 590 identify novel loci implicated in phthalate metabolism. Although some genes seemed to be involved 591 in detoxification of more than one phthalate compound (ie. SULT1C3 for MnBP and MEHP, or 592 SLC17 for oh-MiNP and MEHP), others appeared to be more specific (ie. CYP2C for MEHP while 593 CYP2A for MEP). Third, the study was conducted in a large sample of children from the HELIX 594 project, higher than previous similar studies but still limited in comparison with GWAS of other 595 traits. This study, besides producing novel knowledge about the genes participating in phthalate 596 detoxification and renal excretion, also provides a list of SNPs that can be used to stratify individuals 597 in epidemiological research. Bearing the "alternative" alleles of these SNPs can confer different

susceptibility to phthalate's effects depending on the SNP function (i.e., fast biotransformation to a
neutral compound and then excretion versus fast biotransformation to a more toxic compound).

600

602

601 *4.5. Limitations of the study*

603 However, the study also has some limitations. First, we have restricted our discussion on few genes 604 with interesting functions for phthalate metabolism. However, since SNPs can regulate long distance 605 genes, other genes not highlighted here could also be relevant. Functional analyses in in vitro studies 606 or animal models should be conducted in order to identify the causal variants and genes. Second, we 607 analyzed phthalate metabolites in a pool of two urines and then standardized for creatinine. This has 608 some limitations, especially for pooled samples as discussed elsewhere (O'Brien et al., 2017; 609 Philippat and Calafat, 2021), but currently there is no consensus on how to account for urine dilution 610 in equal volume pools. As discussed above, this could have resulted in the identification of genetic 611 variants that regulate glomerular filtration in general, rather than phthalate excretion in particular. 612 Finally, the analyses were restricted to European ancestry children, thus the translation to other 613 ancestries is unknown.

614 615

616

5. Conclusions

617 In summary, through genome-wide screenings we identified known and novel loci potentially 618 implicated in phthalate metabolism in children. Genes annotated to these loci participate in phase I 619 and phase II metabolism and renal excretion process. Replication of the findings in independent 620 studies and validation in in vitro systems is required.

621 622

623

6. Competing Interests

624 The authors declare that the research was conducted in the absence of any commercial or financial625 relationships that could be construed as a potential conflict of interest.

626 627

7. Author Contributions

628

MB conceptualized the study. MB, LB, ZB, and RN conducted the statistical analysis or functional enrichment analysis with the support of JRG. The HELIX project was coordinated by MV with the support of LM. SA, ALB, MAC, MC, LC, RG, KBG, BH, JL, JS, TCY, JW, are the PIs of the cohorts or participated in sample or data acquisition. AKS was responsible for measurement of phthalate metabolites. MB, GE and CRA participated in genetic data acquisition. LB, ZB and MB wrote the original draft of the paper and all the other co-authors contributed to reviewing and editing the manuscript.

- 636
- 8. Acknowledgements
- 637 638
- 639 We would like to thank all the families for their generous contribution.

640

641 9. Funding

642

The study has received funding from the European Community's Seventh Framework Programme (FP7/2007-206) under grant agreement no 308333 (HELIX project) and the H2020-EU.3.1.2. -Preventing Disease Programme under grant agreement no 874583 (ATHLETE project). The genotyping was supported by the project PI17/01225 and PI17/01935, funded by the Instituto de Salud Carlos III and co-funded by European Union (ERDF, "A way to make Europe") and the Centro Nacional de Genotipado-CEGEN (PRB2-ISCIII).

649

650 BiB received core infrastructure funding from the Wellcome Trust (WT101597MA) and a joint grant 651 from the UK Medical Research Council (MRC) and Economic and Social Science Research Council 652 (ESRC) (MR/N024397/1), and National Institute for Health Research Applied Research 653 Collaboration Yorkshire and Humber (NIHR200166). The views expressed are those of the author(s), 654 and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. INMA 655 data collections were supported by grants from the Instituto de Salud Carlos III, CIBERESP, and the 656 Generalitat de Catalunya-CIRIT. KANC was funded by the grant of the Lithuanian Agency for 657 Science Innovation and Technology (6-04-2014_31V-66). The Norwegian Mother, Father and Child 658 Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Ministry 659 of Education and Research. The Rhea project was financially supported by European projects (EU 660 FP6-2003-Food-3-NewGeneris, EU FP6. STREP Hiwate, EU FP7 ENV.2007.1.2.2.2. Project No 661 211250 Escape, EU FP7-2008-ENV-1.2.1.4 Envirogenomarkers, EU FP7-HEALTH-2009- single 662 stage CHICOS, EU FP7 ENV.2008.1.2.1.6. Proposal No 226285 ENRIECO, EU- FP7- HEALTH-663 2012 Proposal No 308333 HELIX), and the Greek Ministry of Health (Program of Prevention of 664 obesity and neurodevelopmental disorders in preschool children, in Heraklion district, Crete, Greece: 665 2011-2014; "Rhea Plus": Primary Prevention Program of Environmental Risk Factors for 666 Reproductive Health, and Child Health: 2012-15). ISGlobal acknowledges support from the Spanish 667 Ministry of Science and Innovation through the "Centro de Excelencia Severo Ochoa 2019-2023" 668 Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA 669 Program. CRG acknowledge the support of the Spanish Ministry of Science, Innovation, and 670 Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA 671 Programme/Generalitat de Catalunya.

672

LM is funded by a Juan de la Cierva-Incorporación fellowship (IJC2018-035394-I) awarded by the
Spanish Ministerio de Economía, Industria y Competitividad. MC holds a Miguel Servet fellowship
(MS16/00128) funded by Instituto de Salud Carlos III and co-funded by European Social Fund
"Investing in your future".

677

678 **10. Data Availability Statement**

679

Summarized results can be found at <u>https://helixomics.isglobal.org/</u> (THIS WILL BE DONE
 UPON ACCEPTANCE OF THE MANUSCRIPT). The raw data supporting the current study are

available from the corresponding author on request subject to ethical and legislative review. The
"HELIX Data External Data Request Procedures" are available with the data inventory in this
website: http://www.projecthelix.eu/data-inventory.

- 685
- 686

11. References

- 687 688
- Bhattacharyya, M., Basu, S., Dhar, R., Dutta, T.K., 2022. Phthalate hydrolase: distribution,
 diversity and molecular evolution. Environ. Microbiol. Rep. 14, 333–346.
 https://doi.org/10.1111/1758-2229.13028
- Braun, J.M., 2017. Early-life exposure to EDCs: role in childhood obesity and
 neurodevelopment. Nat. Rev. Endocrinol. 13, 161–173.
- 694 https://doi.org/10.1038/nrendo.2016.186
- Bruhn, O., Cascorbi, I., 2014. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2
 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin.
 Drug Metab. Toxicol. 10, 1337–1354. https://doi.org/10.1517/17425255.2014.952630
- Casale, J., Rice, A.S., 2023. Phthalates Toxicity, StatPearls Treasure Island (FL). StatPearls
 Publishing.
- Ceauranu, S., Ciorsac, A., Ostafe, V., Isvoran, A., 2023. Evaluation of the Toxicity Potential of
 the Metabolites of Di-Isononyl Phthalate and of Their Interactions with Members of Family
 1 of Sulfotransferases A Computational Study. Molecules 28, 6748–65.
 https://doi.org/10.3390/molecules28186748/S1
- Choi, K., Joo, H., Campbell, J.L., Clewell, R.A., Andersen, M.E., Clewell, H.J., 2012. In vitro
 metabolism of di(2-ethylhexyl) phthalate (DEHP) by various tissues and cytochrome P450s
 of human and rat. Toxicol. Vitr. 26, 315–22. https://doi.org/10.1016/j.tiv.2011.12.002
- Conrad, D.F., Pinto, D., Redon, R., Feuk, L., Gokcumen, O., Zhang, Y., Aerts, J., Andrews,
 T.D., Barnes, C., Campbell, P., Fitzgerald, T., Hu, M., Ihm, C.H., Kristiansson, K.,
- 709 MacArthur, D.G., MacDonald, J.R., Onyiah, I., Pang, A.W.C., Robson, S., Stirrups, K.,
- Valsesia, A., Walter, K., Wei, J., Tyler-Smith, C., Carter, N.P., Lee, C., Scherer, S.W.,
 Hurles, M.E., 2010. Origins and functional impact of copy number variation in the human
- 711 Hurles, M.E., 2010. Origins and functional impact of copy number variation in th 712 genome. Nature 464, 704–712. https://doi.org/10.1038/nature08516
- D. Turner, S., 2018. qqman: an R package for visualizing GWAS results using Q-Q and
 manhattan plots. J. Open Source Softw. 3, 731–732. https://doi.org/10.21105/joss.00731
- Da Silva, V., Ramos, M., Groenen, M., Crooijmans, R., Johansson, A., Regitano, L., Coutinho,
 L., Zimmer, R., Waldron, L., Geistlinger, L., 2020. CNVRanger: association analysis of
 CNVs with gene expression and quantitative phenotypes. Bioinformatics 36, 972–973.
 https://doi.org/10.1093/bioinformatics/btz632
- Deeley, R.G., Westlake, C., Cole, S.P.C., 2006. Transmembrane transport of endo- and
 xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol.
 Rev. 86, 849–899. https://doi.org/10.1152/PHYSREV.00035.2005
- Domínguez-Romero, E., Scheringer, M., 2019. A review of phthalate pharmacokinetics in
 human and rat: what factors drive phthalate distribution and partitioning? Drug Metab. Rev.
 51, 314–329. https://doi.org/10.1080/03602532.2019.1620762
- Durinck, S., Spellman, P.T., Birney, E., Huber, W., 2009. Mapping identifiers for the integration
 of genomic datasets with the R/Bioconductor package biomaRt. Nat. Protoc. 4, 1184–1191.
 https://doi.org/10.1038/NPROT.2009.97

- 728 Feofanova, E. V., Chen, H., Dai, Y., Jia, P., Grove, M.L., Morrison, A.C., Qi, Q., Daviglus, M., 729 Cai, J., North, K.E., Laurie, C.C., Kaplan, R.C., Boerwinkle, E., Yu, B., 2020. A Genome-730 wide Association Study Discovers 46 Loci of the Human Metabolome in the Hispanic 731 Community Health Study/Study of Latinos. Am. J. Hum. Genet. 107, 849-863. 732 https://doi.org/10.1016/J.AJHG.2020.09.003 733 Frederiksen, H., Skakkebæk, N.E., Andersson, A.M., 2007. Metabolism of phthalates in humans. 734 Mol. Nutr. Food Res. 51, 899–911. https://doi.org/10.1002/mnfr.200600243 735 Gan, B., Yu, L., Yang, H., Jiao, H., Pang, B., Chen, Y., Wang, C., Lv, R., Hu, H., Cao, Z., Ren, 736 R., 2023. Mechanism of agonist-induced activation of the human itch receptor MRGPRX1. 737 PLOS Biol. 21, e3001975. https://doi.org/10.1371/JOURNAL.PBIO.3001975 738 González, J.R., Armengol, L., Solé, X., Guinó, E., Mercader, J.M., Estivill, X., Moreno, V., 739 2007. SNPassoc: An R package to perform whole genome association studies. 740 Bioinformatics 23, 644–645. https://doi.org/10.1093/bioinformatics/btm025 741 Haug, L.S., Sakhi, A.K., Cequier, E., Casas, M., Maitre, L., Basagana, X., Andrusaityte, S., 742 Chalkiadaki, G., Chatzi, L., Coen, M., de Bont, J., Dedele, A., Ferrand, J., Grazuleviciene, 743 R., Gonzalez, J.R., Gutzkow, K.B., Keun, H., McEachan, R., Meltzer, H.M., Petraviciene, 744 I., Robinson, O., Saulnier, P.-J., Slama, R., Sunyer, J., Urquiza, J., Vafeiadi, M., Wright, J., 745 Vrijheid, M., Thomsen, C., 2018. In-utero and childhood chemical exposome in six 746 European mother-child cohorts. Environ. Int. 121, 751–763. 747 https://doi.org/10.1016/J.ENVINT.2018.09.056 748 Hollis-Moffatt, J.E., Phipps-Green, A.J., Chapman, B., Jones, G.T., van Rij, A., Gow, P.J., 749 Harrison, A.A., Highton, J., Jones, P.B., Montgomery, G.W., Stamp, L.K., Dalbeth, N., 750 Merriman, T.R., 2012. The renal urate transporter SLC17A1 locus: Confirmation of 751 association with gout. Arthritis Res. Ther. 14, R92. https://doi.org/10.1186/ar3816 752 Huang, H., Lan, B. Di, Zhang, Y.J., Fan, X.J., Hu, M.C., Qin, G.Q., Wang, F.G., Wu, Y., Zheng, 753 T., Liu, J.H., 2022. Inhibition of Human Sulfotransferases by Phthalate Monoesters. Front. 754 Endocrinol. (Lausanne). 13, 1–9. https://doi.org/10.3389/fendo.2022.868105 755 Kim, S.H., Park, M.J., 2014. Phthalate exposure and childhood obesity. Ann. Pediatr. 756 Endocrinol. Metab. 19, 69–75. https://doi.org/10.6065/APEM.2014.19.2.69 757 Klaassen, C.D., Aleksunes, L.M., 2010. Xenobiotic, bile acid, and cholesterol transporters: 758 Function and regulation. Pharmacol. Rev. 62, 1–96. https://doi.org/10.1124/pr.109.002014 759 Kwan, W.S., Roy, V.A.L., Yu, K.N., 2021. Review on Toxic Effects of Di(2-ethylhexyl) 760 Phthalate on Zebrafish Embryos. Toxics 9, 193–215. 761 https://doi.org/10.3390/TOXICS9080193 762 Lee, D.W., Lim, H.M., Lee, J.Y., Min, K.B., Shin, C.H., Lee, Y.A., Hong, Y.C., 2022. Prenatal 763 exposure to phthalate and decreased body mass index of children: a systematic review and 764 meta-analysis. Sci. Reports 2022 121 12, 1–18. https://doi.org/10.1038/s41598-022-13154-9 765 Lee, S., Lee, H.A., Park, B., Han, H., Hong, Y.S., Ha, E.H., Park, H., 2023. Prospective 766 association between phthalate exposure in childhood and liver function in adolescence: the 767 Ewha Birth and Growth Cohort Study, Environ, Heal, A Glob, Access Sci, Source 22, 1–12. 768 https://doi.org/10.1186/S12940-022-00953-W/FIGURES/2 769 Liu, X., 2019. SLC Family Transporters. Adv. Exp. Med. Biol. 1141, 101–202. 770 https://doi.org/10.1007/978-981-13-7647-4 3 771 Maitre, L., de Bont, J., Casas, M., Robinson, O., Aasvang, G.M., Agier, L., Andrušaitvtė, S.,
- 772
- Ballester, F., Basagaña, X., Borràs, E., Brochot, C., Bustamante, M., Carracedo, A., de
- 773 Castro, M., Dedele, A., Donaire-Gonzalez, D., Estivill, X., Evandt, J., Fossati, S., Giorgis-

- Allemand, L., R Gonzalez, J., Granum, B., Grazuleviciene, R., Bjerve Gützkow, K.,
- 575 Småstuen Haug, L., Hernandez-Ferrer, C., Heude, B., Ibarluzea, J., Julvez, J., Karachaliou,
- 776 M., Keun, H.C., Hjertager Krog, N., Lau, C.-H.E., Leventakou, V., Lyon-Caen, S.,
- 777 Manzano, C., Mason, D., McEachan, R., Meltzer, H.M., Petraviciene, I., Quentin, J.,
- 778 Roumeliotaki, T., Sabido, E., Saulnier, P.-J., Siskos, A.P., Siroux, V., Sunyer, J., Tamayo,
- I., Urquiza, J., Vafeiadi, M., van Gent, D., Vives-Usano, M., Waiblinger, D., Warembourg,
- 780 C., Chatzi, L., Coen, M., van den Hazel, P., Nieuwenhuijsen, M.J., Slama, R., Thomsen, C.,
- 781 Wright, J., Vrijheid, M., 2018. Human Early Life Exposome (HELIX) study: a European
- population-based exposome cohort. BMJ Open 8, e021311.
- 783 https://doi.org/10.1136/bmjopen-2017-021311
- Maywald, M.L., Picciotto, C., Lepa, C., Bertgen, L., Yousaf, F.S., Ricker, A., Klingauf, J.,
 Krahn, M.P., Pavenstädt, H., George, B., 2022. Rap1 Activity Is Essential for Focal
 Adhesion and Slit Diaphragm Integrity. Front. Cell Dev. Biol. 10, 790365, 1–14.
 https://doi.org/10.3389/FCELL.2022.790365/BIBTEX
- Nurtdinov, R., Guigó, R., n.d. EPIraction an atlas of candidate enhancer-gene interactions in
 human tissues and cell lines. [Manuscript in preparation].
- O'Brien, K.M., Upson, K., Buckley, J.P., 2017. Lipid and Creatinine Adjustment to Evaluate
 Health Effects of Environmental Exposures. Curr. Environ. Heal. reports 4, 44–50.
 https://doi.org/10.1007/S40572-017-0122-7/FIGURES/2
- Pazoki, R., Vujkovic, M., Elliott, J., Evangelou, E., Gill, D., Ghanbari, M., van der Most, P.J.,
 Pinto, R.C., Wielscher, M., Farlik, M., Zuber, V., de Knegt, R.J., Snieder, H., Uitterlinden,
 A.G., Boezen, H.M., Franke, L., van der Harst, P., Navis, G., Rots, M., Swertz, M.,
 Welfforderteil P.H.P., Wiinserger, C., Length, L.A., Jiang, X., Said, S., Karlan, D.F., Length, J.A., Jiang, Y., Said, S., Karlan, D.F., Jang, Y., Said, S., Karlan, Jang, Y., Said, S., Karlan, D.F., Jang, Y., Said, S., Karlan, Jang, Y., Sa
- Wolffenbuttel, B.H.R., Wijmenga, C., Lynch, J.A., Jiang, X., Said, S., Kaplan, D.E., Lee,
- 797 K.M., Serper, M., Carr, R.M., Tsao, P.S., Atkinson, S.R., Dehghan, A., Tzoulaki, I., Ikram,
- 798 M.A., Herzig, K.H., Järvelin, M.R., Alizadeh, B.Z., O'Donnell, C.J., Saleheen, D., Voight,
- B.F., Chang, K.M., Thursz, M.R., Elliott, P., Ballas, Z.K., Bhushan, S., Boyko, E.J., Cohen,
 D.M., Concato, J., Aslan, M., Zhao, H., Constans, J.I., Dellitalia, L.J., Fayad, J.M.,
- D.M., Concato, J., Asian, M., Zhao, H., Constans, J.I., Delintaria, L.J., Fayad, J.M.,
 Fernando, R.S., Florez, H.J., Gaddy, M.A., Gappy, S.S., Gibson, G., Godschalk, M., Greco,
- J.A., Gupta, S., Gutierrez, S., Hammer, K.D., Hamner, M.B., Harley, J.B., Hung, A.M.,
- Bull, Supra, S., Sutteriez, S., Hammer, R.D., Hammer, W.D., Hamey, S.D., Hang, F.H.,
 Huq, M., Hurley, R.A., Iruvanti, P.R., Ivins, D.J., Jacono, F.J., Jhala, D.N., Kaminsky, L.S.,
- 804 Klein, J.B., Liangpunsakul, S., Lichy, J.H., Moser, J., Huang, G.D., Muralidhar, S.,
- 805 Mastorides, S.M., Mathew, R.O., Mattocks, K.M., McArdle, R., Meyer, P.N., Meyer, L.J.,
- 806 Moorman, J.P., Morgan, T.R., Murdoch, M., Okusaga, O.O., Oursler, K.A.K., Ratcliffe,
- 807 N.R., Rauchman, M.I., Robey, R.B., Ross, G.W., Servatius, R.J., Sharma, S.C., Sherman,
- 808 S.E., Sonel, E., Sriram, P., Stapley, T., Striker, R.T., Tandon, N., Villareal, G., Wallbom,
- A.S., Wells, J.M., Whittle, J.C., Whooley, M.A., Wilson, P.W., Sun, Y. V., Xu, J., Yeh,
- 810 S.S., Connor, T., Argyres, D.P., Hauser, E.R., Beckham, J.C., Stephens, B., Aguayo, S.M.,
- Ahuja, S.K., Pyarajan, S., Cho, K., Gaziano, J.M., Kinlay, S., Nguyen, X.M.T., Brewer, J.
- V., Brophy, M.T., Do, N. V., Humphries, D.E., Selva, L.E., Shayan, S., Whitbourne, S.B.,
 Breeling, J.L., Romero, J.P.C., Ramoni, R.B., 2021. Genetic analysis in European ancestry
- individuals identifies 517 loci associated with liver enzymes. Nat. Commun. 12, 2579, 1–
 12. https://doi.org/10.1038/S41467-021-22338-2
- Pedersen, B.S., Quinlan, A.R., 2017. Who's Who? Detecting and Resolving Sample Anomalies
 in Human DNA Sequencing Studies with Peddy. Am. J. Hum. Genet. 100, 406–413.
 https://doi.org/10.1016/j.ajhg.2017.01.017
- 819 Philippat, C., Calafat, A.M., 2021. Comparison of strategies to efficiently combine repeated

- urine samples in biomarker-based studies. Environ. Res. 192, 110275, 1–9.
- 821 https://doi.org/10.1016/J.ENVRES.2020.110275
- Pinto, N., Eileen Dolan, M., 2011. Clinically Relevant Genetic Variations in Drug Metabolizing
 Enzymes. Curr. Drug Metab. 12, 487–497. https://doi.org/10.2174/138920011795495321
- Praveena, S.M., Teh, S.W., Rajendran, R.K., Kannan, N., Lin, C.C., Abdullah, R., Kumar, S.,
- 825 2018. Recent updates on phthalate exposure and human health: a special focus on liver
 826 toxicity and stem cell regeneration. Environ. Sci. Pollut. Res. 25, 11333–11342.
- 827 https://doi.org/10.1007/s11356-018-1652-8
- Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller, J., Sklar,
 P., de Bakker, P.I., Daly, M.J., Sham, P.C., 2007. PLINK: a tool set for whole-genome
 association and population-based linkage analyses. Am J Hum Genet 81, 559–575.
- 831 Ramírez-Cosmes, A., Reyes-Jiménez, E., Zertuche-Martínez, C., Hernández-Hernández, C.A.,
- García-Román, R., Romero-Díaz, R.I., Manuel-Martínez, A.E., Elizarrarás-Rivas, J.,
 Vásquez-Garzón, V.R., 2021. The implications of ABCC3 in cancer drug resistance: can we
 use it as a therapeutic target? Am. J. Cancer Res. 11, 4127–40.
- Sakhi, A.K., Sabaredzovic, A., Cequier, E., Thomsen, C., 2017. Phthalate metabolites in
 Norwegian mothers and children: Levels, diurnal variation and use of personal care
 products. Sci. Total Environ. 599–600, 1984–1992.
- 838 https://doi.org/10.1016/J.SCITOTENV.2017.05.109
- Schlosser, P., Li, Y., Sekula, P., Raffler, J., Grundner-Culemann, F., Pietzner, M., Cheng, Y.,
 Wuttke, M., Steinbrenner, I., Schultheiss, U.T., Kotsis, F., Kacprowski, T., Forer, L.,
 Hausknecht, B., Ekici, A.B., Nauck, M., Völker, U., Walz, G., Oefner, P.J., Kronenberg, F.,
 Mohney, R.P., Köttgen, M., Suhre, K., Eckardt, K.U., Kastenmüller, G., Köttgen, A., 2020.
 Genetic studies of urinary metabolites illuminate mechanisms of detoxification and
- excretion in humans. Nat. Genet. 52, 167–176. https://doi.org/10.1038/S41588-019-0567-8
 Stajnko, A., Runkel, A.A., Kosjek, T., Snoj Tratnik, J., Mazej, D., Falnoga, I., Horvat, M., 2022.
- Assessment of susceptibility to phthalate and DINCH exposure through CYP and UGT
 single nucleotide polymorphisms. Environ. Int. 159, 107046, 1–13.
 https://doi.org/10.1016/j.opyint.2021.107046
- 848 https://doi.org/10.1016/j.envint.2021.107046
- Stanzick, K.J., Li, Y., Schlosser, P., Gorski, M., Wuttke, M., Thomas, L.F., Rasheed, H., Rowan,
 B.X., Graham, S.E., Vanderweff, B.R., Patil, S.B., Robinson-Cohen, C., Gaziano, J.M.,
 O'Donnell, C.J., Willer, C.J., Hallan, S., Åsvold, B.O., Gessner, A., Hung, A.M., Pattaro,
 C., Köttgen, A., Stark, K.J., Heid, I.M., Winkler, T.W., 2021. Discovery and prioritization
- of variants and genes for kidney function in >1.2 million individuals. Nat. Commun. 12,
 4350, 1–17. https://doi.org/10.1038/S41467-021-24491-0
- Takeuchi, F., McGinnis, R., Bourgeois, S., Barnes, C., Eriksson, N., Soranzo, N., Whittaker, P.,
 Ranganath, V., Kumanduri, V., McLaren, W., Holm, L., Lindh, J., Rane, A., Wadelius, M.,
 Deloukas, P., 2009. A genome-wide association study confirms VKORC1, CYP2C9, and
 CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5, e1000433, 1–9.
- 859 https://doi.org/10.1371/JOURNAL.PGEN.1000433
- Torres, A.M., Dnyanmote, A. V., Granados, J.C., Nigam, S.K., 2021. Renal and non-renal
 response of ABC and SLC transporters in chronic kidney disease. Expert Opin. Drug
 Metab. Toxicol. 17, 515–542. https://doi.org/10.1080/17425255.2021.1899159
- 863 Visscher, P.M., Wray, N.R., Zhang, O., Sklar, P., McCarthy, M.I., Brown, M.A., Yang, J., 2017.
- 864 10 Years of GWAS Discovery: Biology, Function, and Translation. Am. J. Hum. Genet.
- 865 101, 5–22. https://doi.org/10.1016/j.ajhg.2017.06.005

- Vogel, N., Schmidt, P., Lange, R., Gerofke, A., Sakhi, A.K., Haug, L.S., Jensen, T.K.,
- 867 Frederiksen, H., Szigeti, T., Csákó, Z., Murinova, L.P., Sidlovska, M., Janasik, B.,
- 868 Wasowicz, W., Tratnik, J.S., Mazej, D., Gabriel, C., Karakitsios, S., Barbone, F., Rosolen,
- 869 V., Rambaud, L., Riou, M., Murawski, A., Leseman, D., Koppen, G., Covaci, A., Lignell,
- 870 S., Lindroos, A.K., Zvonar, M., Andryskova, L., Fabelova, L., Richterova, D., Horvat, M.,
- 871 Kosjek, T., Sarigiannis, D., Maroulis, M., Pedraza-Diaz, S., Cañas, A., Verheyen, V.J.,
- Bastiaensen, M., Gilles, L., Schoeters, G., Esteban-López, M., Castaño, A., Govarts, E.,
- Koch, H.M., Kolossa-Gehring, M., 2023. Current exposure to phthalates and DINCH in
- 874 European children and adolescents Results from the HBM4EU Aligned Studies 2014 to
- 875 2021. Int. J. Hyg. Environ. Health 249, 114101, 1–11.
- 876 https://doi.org/10.1016/J.IJHEH.2022.114101
- Wang, I.J., Karmaus, W.J.J., 2017. Oxidative Stress-Related Genetic Variants May Modify
 Associations of Phthalate Exposures with Asthma. Int. J. Environ. Res. Public Health 14,
 162–75. https://doi.org/10.3390/IJERPH14020162
- Wang, K., Li, M., Hadley, D., Liu, R., Glessner, J., Grant, S.F.A., Hakonarson, H., Bucan, M.,
 2007. PennCNV: An integrated hidden Markov model designed for high-resolution copy
 number variation detection in whole-genome SNP genotyping data. Genome Res. 17, 1665–
 1674. https://doi.org/10.1101/GR.6861907
- Wang, X.X., Wang, D., Luo, Y., Myakala, K., Dobrinskikh, E., Rosenberg, A.Z., Levi, J., Kopp,
 J.B., Field, A., Hill, A., Lucia, S., Qiu, L., Jiang, T., Peng, Y., Orlicky, D., Garcia, G.,
 Herman-Edelstein, M., D'Agati, V., Henriksen, K., Adorini, L., Pruzanski, M., Xie, C.,
 Krausz, K.W., Gonzalez, F.J., Ranjit, S., Dvornikov, A., Gratton, E., Levi, M., 2018.
 FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity. J.
 Am. Soc. Nephrol. 29, 118–137. https://doi.org/10.1681/ASN.2017020222
- Wang, Y., Zhu, H., Kannan, K., 2019. A Review of Biomonitoring of Phthalate Exposures.
 Toxics 7, 1–28. https://doi.org/10.3390/TOXICS7020021
- Watanabe, K., Taskesen, E., Van Bochoven, A., Posthuma, D., 2017. Functional mapping and
 annotation of genetic associations with FUMA. Nat. Commun. 8, 1826–36.
 https://doi.org/10.1038/s41467-017-01261-5
- Wickham, H., 2016. ggplot2: Elegant Graphics for Data Analysis, Use R! Springer Cham.
 https://doi.org/10.1007/978-3-319-24277-4
- Williams, M.J., Wiemerslage, L., Gohel, P., Kheder, S., Kothegala, L. V., Schiöth, H.B., 2016.
 Dibutyl Phthalate Exposure Disrupts Evolutionarily Conserved Insulin and Glucagon-Like
 Signaling in Drosophila Males. Endocrinology 157, 2309–2321.
- 900 https://doi.org/10.1210/EN.2015-2006
- Zhu, B., Cao, A., Li, J., Young, J., Wong, J., Ashraf, S., Bierzynska, A., Menon, M.C., Hou, S.,
 Sawyers, C., Campbell, K.N., Saleem, M.A., He, J.C., Hildebrandt, F., D'Agati, V.D., Peng,
 W., Kaufman, L., 2019. Disruption of MAGI2-RapGEF2-Rap1 signaling contributes to
- 904 podocyte dysfunction in congenital nephrotic syndrome caused by mutations in MAGI2.
- 905 Kidney Int. 96, 642–55. https://doi.org/10.1016/J.KINT.2019.03.016
- 906
- 907 908

910 Tables

911

Table 1. Descriptive of the study population

percentage % are reported. LMW: low molecular weight. HMW: high	¥	1
Variable	N (%), Mean (SD)	N missing
Cohort		
BiB (UK)	90 (8.62%)	0
EDEN (France)	135 (12.93%)	0
KAUNAS (Lithuania)	196 (18.77%)	0
MoBa (Norway)	239 (22.89%)	0
RHEA (Greece)	186 (17.82%)	0
INMA (Spain)	198 (18.97%)	0
Child's sex		
Females	473 (45.31%)	0
Males	571 (54.69%)	0
Child's age (years)	7.96 (1.54)	0
Child's obesity		
Normal	830 (79.50%)	0
Overweight	155 (14.85%)	0
Obese	59 (5.66%)	0
Maternal education		
Primary	115 (11.02%)	0
Secondary	353 (33.81%)	0
University or higher	550 (52.68%)	0
Urinary creatinine levels (g per ml of urine)	1.004 (0.350)	0
Urinary LMW phthalate levels (µg per g of creatinine)		
MBzP	8.85 (16.14)	0
MEP	77.32 (184.98)	0
MiBP	57.48 (60.29)	0
MnBP	33.78 (37.75)	0
Urinary HMW phthalate levels (µg per g of creatinine)		
MEHP	4.67 (11.09)	34
MECPP*	53.56 (131.78)	0
MEHHP*	31.20 (84.53)	3
MEOHP*	18.80 (46.17)	1
oh-MiNP	9.09 (16.20)	0
oxo-MiNP**	5.62 (15.82)	0

For continuous variables mean and SD are shown, while for categorical variables the sample size and its percentage % are reported. LMW: low molecular weight. HMW: high molecular weight. N=1,044.

*Metabolites of MEHP, **Metabolite of oh-MiNP

912

913

915

Table 2. Summary of the results of the single-trait GWAS of phthalate levels and their ratios

A locus is defined as a region of 1 Mb with SNPs with similar effect size on the trait Suggestive statistical significance is set at p-value <1E-05

Class	Phthalate	N	Lambda	N genome- wide sig. SNPs	N genome- wide sig. loci	N suggestive sig. SNPs	N suggestive sig. loci	Minimum p-value
LMW	MBzP	1044	0.996	1	1	30	6	4.28E-08
LMW	MEP	1044	0.997	0	0	21	8	9.37E-07
LMW	MiBP	1044	1.007	0	0	62	7	1.80E-07
LMW	MnBP	1044	1.008	0	0	58	10	4.98E-07
HMW	MEHP	1010	1.000	0	0	25	11	1.39E-06
HMW	MEHHP	1041	1.018	0	0	128	15	6.17E-08
HMW	MECPP	1044	1.021	0	0	505	15	1.36E-07
HMW	MEOHP	1043	1.018	0	0	67	12	2.66E-07
HMW	oh-MiNP	1044	1.013	0	0	32	12	2.23E-06
HMW	oxo-MiNP	1044	0.987	0	0	17	5	1.33E-06
HMW ratio	MEHHP_MEHP	1009	0.986	0	0	83	11	3.62E-07
HMW ratio	MECPP_MEHP MECPP_MEHH	1010	0.987	369	1	563	11	2.10E-20
HMW ratio	Р	1041	1.017	774	2	1091	11	1.45E-63
HMW ratio	MEOHP_MEHP MEOHP_MEHH	1009	0.986	0	0	417	12	5.72E-07
HMW ratio	P oxo-MiNP_oh-	1040	1.006	186	1	307	11	2.81E-14
HMW ratio	MiNP	1044	0.999	2	1	66	7	4.15E-08
	Total*			1332	6	3472	164	
	Total**					2140	158	
	Total unique*				4		117	
	Total unique**						113	

*including genome-wide significant SNPs


**without including genome-wide significant SNPs

916

cus is	s defined as a region of 1M	b with SNPs with s	imilar R2 on the trait													
lead :	SNPs is the SNP with the lo	west p-value in th	e locus. If more than	one, then or	e is arbitrary	selected a	nd sho wn.									
cordi	ing to the notation for the	ead SNPs of the si	ngle-tra it GWAS													
n brac	chets suggestive associati	o ns														
After	rannotation with FUMA, th	us including SNPs	not genotyped but in	lin ka ge dise	q ui li bri u m											
12*	Ph th alate **	Chr Pos_hg 19	Lead SNP	Non-Effi effectalle allele	ect Beta lle	Standar derror	P-value	N S NPs / in i locus** e	ndepend		Relative gene position	O ther genes in locus	eQTLs	Gene-enhancer interactions	GWAS catalog	Candidate gene function
	MECPP_MEHPP; MECPP_MEHP; MEOHP_MEHHP; (MECPP); (MEOHP_MEHP)	10 96719845	rs74494115	G T	-0.308	7 0.0171	1.45E-63	1132	26 0	CYP2C9	Intronic	MYOF; FRA19AC1; LGI1; SLC35G1; PLCE1; NOC3L; TBC1D12; HELLS; CYP2C18; CYP2C19; CYP2C8; C10arf129; PDLM1; SORB51; ALDH18A1; TCTN3; ENTPD1; CCNJ; M2; others	FRA19AC1; LGH; SLC35G1; NOC3L; TBC1D12; HELLS; CYP2C18; CYP2C19; CYP2C8; C10off129; PDLM1; ALDH18A1; TCTN3; ENTPD1; M2 (in trans))	Liver (LGH; SLC35G1; PLCE1; NOC3L; TBC1D12; HELLS; CYP2C18; CYP2C19; CYP2C8; CYP2C18; CYP2C19; (NOC3L; TBC1D12; HELLS; CYP2C18; CYP2C9; CYP2C8; PDLM1; SORSB1; ALDH1BA1; TCTN3; ENTPD1; CCNJ)	Serum/plasma metabolite levels; liver enzyme levels (alkaline phosphatase); drug response/metabolization (ex. warfarin); gout	Cytochrome P450 monooxygenases: Catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids: CYP2C8 (kronobioli CYP2C9 (kronobiolics); CYP2C18 (unknown); and CYP2 (kronobiolics)// SLC3567 (Solute Carrier Family 35 Me G1): Drughreabolite transporter protein.
	MECPP_MEHPP; (MECPP); (MEOPH_MEHP); (MEHHP_MEHP); (oh- MINP)	6 25809716	rs1359232	C A	-0.133	5 0.0156	4.58E-17	462	12 5	SCL17A1	Intronic	SCGN; HIST1H cluster; SCL17A2; SLC17A3; SLC17A4; TRIM38; GPX5; GPX6 and others	Liver (SLC17A1; SLC17A3; SLC17A4); kidney (SLC17A3); others	Liver (SCGN; SLC17A1; SLC17A2; SLC17A3; SCL17A4; HIST1H cluster and others) ; kidney (SCL17A1; SCL17A3; SCL17A3)	Urate levels; urinary metabolite levels; serum/plasma metabolite levels; gout; diastolic blood pressure; hematocrit; estimated glomerular filtration rate (creatinine)	Solute Carrier Family 17 Members: Facilitate transpor molecules across membranes: SLC17A4 (phospate exc SLC17A1 and SLC17A3 (urate excretion); SLC17A2 (acid transport) // Glutathione Peroxides Members: G and GPX6 (reduction of hydrogen peroxide, organic
	oxo-MiNP_oh-MiNP; (MEOHP_MEHHP)	3 34882408	rs80064213	т с	0.330	7 0.0598	4.15E-08	59	2 /	FECHP1	Intergenic	PDCD6IP; ARPP21; STAC; DCLK3	None	None	Body mass index; breast cancer	hydroperoxides and lipid hydroperoxides) STAC (SH3 And Cysteine Rich Domain): Predicted to enable transmembrane transporter binding activity.
	MBzP	9 134523638	rs138702233	СТ	0.393	8 0.0713	4.29E-08	40	2 /	RAPGEF1	Intronic	AIF1L; NUP214; FAM78A; PPAPDC3; PRRC2B; POMT1; UCK1; MED27; NTNG2; SETX; TTF1, C9orf171; DDX31; GTF3C4; AK8; C9orf9; TSC1; GF11B	Several but not liver or kidney (AIF1L; PPAPDC3; PRRC2B; POMT1, RAPGEF1)	Liver (AIF1L; NUP214; POMT1; UCK1; RAPGEF1); kidney (FAM78A; POMT1; UCK1; RAPGEF1; MED27; NTNG2)	None	RAPCEF1 (Rap Guanine Nucleotide Exchange Facto Human guanine nucleotide exchange factor. It is related to Nephrotic Syndrome, Type 7 and Membranoproliferative Glomerulonephritis.
	(MEHHP); (MEOHP); (MECPP)	2 107637715	rs77376475	A G	0.309	2 0.0567	6.17E-08	2	1/	AC005040.3	Intergenic	SULT1C3; ST6GAL2	Dorsolateral Prefrontal Cortex (ST6GAL2)	None	None	SULT1C3 (Sulfotransferase Family 1C Member 3): 5
	(MEOHP_MEHHP)	1 242361140	rs10926644	тс	-0.052	2 0.0097	8.43E-08	31	2 F	PLD5	Intronic	CHRM3; FH; KMO; CHML; WDR84; EXOI; MAPILC3C; CEP170; SDCCAG8; ZBTB18; ADSS; C1orf101	Brain (PLD5)	None	Response to cytadine analogues (cytosine arabinoside); total PHF-tau	conjugation of endogenous compounds and xenobilities. <i>FH Furmates</i> Hydratase): Enzyme of the Krebs cycle catalyzes the formation of L-malate from fumerate. // KM (<i>Kyrunerina</i> 5: Admocozygenase): Catalyzes the hydr of L-trytophan metabolite, L-kynurerine, to form L-3- hydroxyhyrurerina. <i>FIDES</i> (<i>Fhospholipase</i> D Family Member 5): Predicted to enable catalytic activity. // AD (<i>Admy/Sourciates</i> Synthase 2): Catalyzes the first committed step in the conversion of inosine monophosph adenosine monophosphate.
	(MEOHP); (MEHHP); (MECPP); (MECPP_MEHP); (MEHHP_MEHP)	18 76807781	18:76807781:G:A	A G	0.145	8 0.0288	5.00E-07	116	2 \$	SALL3	Intergenic	GALR1; HSBP1L1; PARD6G-AS1; NFATC1; ATP9B	Several but not liver or kidney (GALR1; HSBP1L1; PARD6G-AS1; NFATC1; ATP9B)	Kidney and liver (ATP9B)	Frontotemporal dementia	ATP9B (ATPase Phospholipid Transporting 9B - Putative): Predicted to enable ATPase-coupled intramembrane lipid transporter activity.
	(MECPP_MEHPP)	19 49250239	19:49250239:C:T	тс	-0.076	5 0.0161	2.42E-06	104	17	ZUMO1	Intergenic	SLCBA2; PLA2G4C; CARDB, SULT2B1; FAM83E; SPAC4, RPL18; SPHR2; DBP; CA11; NITN5; FUT2; MAIMSTR; RASIP1; FUT1; FGP21, BCA72; HSD17B14; BAX; FTL; GYS1; RUVBL2; LHB; others	Sewani Issues (PLA2645; CARD8, SULT281; FANBES: RPI II:85PH/R2; DBP; CA11; NTN6; FUT2; MANSTR; RASIPH; LUMOI - Johney; FUT1; BCAT2; HSD17B14; RUVBL2)	RASIP1; FUT1; FGF21; HSD17B14; BCAT2); kidney (FAM38E; RPL18; SPHK2; DBP; CA11; NTN5; FUT2; MAMSTR; RASIP1; FUT1;	plasma proteins; intestinal-type alkaline phosphatase levels; liver enzyme levels (gamma-glutamyl transferase); urinary	ISD 17814 (Hydraxysteroid 17-Beta Dehydrogenas Metabolism of takenida and also of other substrates, suc fatty acids, prostaglandins, and wanobiolics. // SLCB42, Carrier Family 8 Member 423: Predicted to enable calciumcation antiporter activity, innohed in regulation or postsynaptic cyclosofic calcium in concentration and calciumsodium antiporter activity, // SULT281 (Sulforansferses Family 28 Member 17: Sulfate conj of many hormones, neurotransmitters, drugs, and xanobi comocunds.
9	(MEOHP_MEHP)	17 48751114	rs72837555	с т	-0.147	2 0.0319	4.54E-06	12	1 /	ABCC3	Intronic	CHAD; RSAD1; MYCBPAP; EPN3; SPATA20; CACNA1G; ANKRD40; LUC7L3; WFIKKN2; TOB1; NME1- NME2	Several tissues but not liver or kidney (SPAT20; ABCC3; ANKRD40; WFIKKN2; NME1-NME2)	Liver (ABCC3; ANKRD40; LUC7L3)	Serum/plasma metabolite levels	ABCC3 (ATP Binding Cassette Subfamily C Member Member of the superfamily of ATP-binding cassette (AB transporters of molecules across extra- and intra-cellular membranes. Involved in multi-drug resistance.
10	(MEP)	19 41148101	rs2561564	ΤG	-0.312	4 0.0684	5.61E-06	2	1 /	TBP4	Intergenic	AKT2, C19orf47, PLD3, SERTAD1, SERTAD3, SHKBP1, NUMBL, ADCK4, ITPKC, C19orf54, SNRPA, MIA, MIA-RAB4B, RAB4B, RAB4B- EGLN2, EGLN2, CYP2A6, CYP2B6, CYP2A13, CYP2S1, others	Several but not liver or kidney (SERTAD1; SHKBP1; LTBP4; NUMBL; ADCK4; ITPKC; C190/54, RAB4B; RAB4B- EGLN2; EGLN2)	Liver (CYP2A13)	None	Cytochrome P450 monocytograsses: Catalyze many reactions involved in drug metabolism and synthesis of cholesterol; steroids and other injdis: CYP2266 (xenobic CYP286 (xenobiotics); CYP2A13 (a major nitrosamine specific to tobacco); and CYP2S1 (carcinogens).
	(MnBP)	4 70619038		G C		0.041	7.6E-06	46		SULT1B1	Intronic	TMPRSS11BNL: TPRSS11B; UGT1B11; UGT2A1; UGT2A2; UGT2A2; SULT1B1; SULT1E1; CSN1S1; ODAM; FDCSP; CSN3; PROL1; AMTN	Several Issues (UGT2B11; SULT1B1 - liver; SULT1E1; CSN1S1)	Liver (FDCSP; PROL1; AMTN)	Uterine fibroids	UDP Glucuronosylransferase Family 2 Members: L conjugato and subsequent elimination of potentially tox xenobiotics and endogenous compounds: UGTBH1 (en metabolic process and xenobiotic glucuroridation); UG1 and UGT2A2 (clearing lipophilic odorant molecules from nasal sensory epithelium). / Sultotransferase Family Members: Sulfate conjugation of many hormones, neurotransmitters, drugs, and avenobiotics: SULT1B1; SULT1E1 (transfers a sulto molety to and from estore, may control loves of o strogen receptors).
12	(MECPP_MEHPP); (MEHHP_MEHP)	8 30424915	8:30424915:A:G	G A	-0.085	1 0.0189	7.74E-06	161	17	RBPMS	Intronic	INTS9; HMBOX1; DUSP4; TMEM66; LEPROTL1; MBOAT4; DCTN6; GTF2E2; SMIM18; GSR; PPP2CB; PURG: WRN	Several tissues but not liver or kidney (TMEM66; RBPMS; GTF2F2; SMIM18; GSR; PPP2CB)	Liver (TMEM66; LEPROTL1; GTF2E2; SMM18; PPP2CB; PURG); Bladder (MBOAT4; DCTN6)	None	GSR (Glutathione-Disulfide Reductase): Central enzy cellular antioxidant defence, and reduces oxidized glutati disulfide (GSSG) to the sulfhydryl form GSH, which is an important cellular antioxidant.








922 923 924 925 926 927 928

Figure 1. Summary of the phthalate metabolites and ratios included in the study.

Diagram showing the phthalate metabolites included in the study, along with their precursor phthalates and intermediate metabolites. Low-molecular-weight metabolites (LWM) in the study are coloured in blue and highmolecular weight metabolites (HMW) in the study are coloured in green. Orange arrows represent the metabolic reactions whose ratio is included in the study (product/substrate).




930 Figure 2. Miami plot of the association between common SNPs (top panel) and CNVs (bottom panel) vs

931 phthalate levels or ratios

932 Each dot represents the association of a SNP or CNV. The x-axis indicates the position of the SNP or CNV in the 933 genome. The y-axis shows the statistical significance, the -log10(p-value). Colours indicate the phthalate compound

934 or ratio the SNPs or CNVs are associated with. The SNPs/CNVs passing multiple-testing correction (5E-08 for


- 935 SNPs and 1.39E-03 for CNVs) are annotated to the closest gene.
- 936
- 937



938 Figure 3. Locus zoom of the SNP-associated regions identified after multiple-testing correction

Each dot represents the association of a SNP. The lead SNPs are coloured in dark purple, other lead SNPs (SNPs in the region with LD <0.1 with top lead SNP) in light purple and independent significant SNPs in red. Other SNPs are coloured according to their linkage disequilibrium (r^2) with the lead SNP. The y-axis shows the statistical significance, the -log10(p-value). The x-axis indicates the position of the SNP in the genome. FUMA prioritized coding genes and FUMA non-prioritized coding and non-coding genes are shown.

- 944 945
- 946
- 947
- 948
- 949 950
- 951
- 952
- 953



954

955 Figure 4. Locus zoom of the consensus CNV-associated regions identified after multiple-testing correction

Each line represents an CNV region in a single sample. Single gain CNVs are coloured in red, single loss CNVs in
blue and double loss CNVs in dark blue. The y-axis shows the number of individuals presenting a CNV for the
specific region. The x-axis shows the genomic coordinates. Rhombus represent the SNPs used to detect the CNVs,

959 and genes in the regions are also shown.